Attenuated Salmonella choleraesuis-mediated RNAi targeted to conserved regions against foot-and-mouth disease virus in guinea pigs and swine

被引:11
作者
Cong, Wei [1 ]
Jin, Hong [1 ]
Jiang, Chengda [1 ]
Yan, Weiyao [1 ]
Liu, Mingqiu [1 ]
Chen, Jiulian [2 ]
Zuo, Xiaoping [2 ]
Zheng, Zhaoxin [1 ]
机构
[1] Fudan Univ, Sch Life Sci, Inst Genet, State Key Lab Genet Engn, Shanghai 200433, Peoples R China
[2] Jinyu Grp Co Ltd, Biopharm, Inner Mongolia 010020, Peoples R China
关键词
foot-and-mouth disease virus; RNA interference; Salmonella choleraesuis; conserved sequence; swine; SMALL INTERFERING RNA; ORAL DNA VACCINATION; IN-VITRO; HUMAN-CELLS; INHIBITION; INFECTION; TYPHIMURIUM; SIRNA; VACCINES; CARRIER;
D O I
10.1051/vetres/2010002
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
In this study, specific sequences within three genes (3D, VP4 and 2B) of the foot-and-mouth disease virus (FMDV) genome were determined to be effective RNAi targets. These sequences are highly conserved among different serotype viruses based on sequence analysis. Small interfering RNA (siRNA)expressing plasmids (p3D-NT19, p3D-NT56, pVP4-NT19, pVP4-NT65 and p2B-NT25) were constructed to express siRNA targeting 3D, VP4 and 2B, respectively. The antiviral potential of these siRNA for various FMDV isolates was investigated in baby hamster kidney (BHK-21) cells and suckling mice. The results show that these siRNA inhibited virus yield 10- to 300-fold for different FMDV isolates of serotype O and serotype Asia I at 48 h post infection in BHK-21 cells compared to control cells. In suckling mice, p3D-NT56 and p2B-NT25 delayed the death of mice. Twenty percent to 40% of the animals that received a single siRNA dose survived 5 days post infection with serotype O or serotype Asia I. We used an attenuated Salmonella choleraesuis (C500) vaccine strain, to carry the plasmid that expresses siRNA directed against the polymerase gene 3D (p3D-NT56) of FMDV. We used guinea pigs to evaluate the inhibitory effects of recombinant S. cho (p3D-NT56/S. cho) on FMDV infection. The results show that 80% of guinea pigs inoculated with 10(9) CFU of p3D-NT56/S. cho and challenged 36 h later with 50 ID50 of homologous FMDV were protected. We also measured the antiviral activity of p3D-NT56/S. cho in swine. The results indicate that 100% of the animals treated with 5 x 10(9) CFU of p3D-NT56/S. cho were protected in 9 days.
引用
收藏
页数:13
相关论文
共 49 条
[1]   FOOT-AND-MOUTH DISEASE [J].
BACHRACH, HL .
ANNUAL REVIEW OF MICROBIOLOGY, 1968, 22 :201-+
[2]   A review of emergency foot-and-mouth disease (FMD) vaccines [J].
Barnett, PV ;
Carabin, H .
VACCINE, 2002, 20 (11-12) :1505-1514
[3]   Inhibition of respiratory viruses by nasally administered siRNA [J].
Bitko, V ;
Musiyenko, A ;
Shulyayeva, O ;
Barik, S .
NATURE MEDICINE, 2005, 11 (01) :50-55
[4]   Pathogenesis of wild-type and leaderless foot-and-mouth disease virus in cattle [J].
Brown, CC ;
Piccone, ME ;
Mason, PW ;
McKenna, TSC ;
Grubman, MJ .
JOURNAL OF VIROLOGY, 1996, 70 (08) :5638-5641
[5]   Adenovirus-mediated RNA interference against foot-and-mouth disease virus infection both in vitro and in vivo [J].
Chen, WZ ;
Liu, MQ ;
Jiao, Y ;
Yan, WY ;
Wei, XF ;
Chen, JL ;
Fei, L ;
Liu, Y ;
Zuo, XP ;
Yang, FG ;
Lu, YG ;
Zheng, ZX .
JOURNAL OF VIROLOGY, 2006, 80 (07) :3559-3566
[6]   RNA interference taraetina VP1 inhibits foot-and-mouth disease virus replication in BHK-21 cells and suckling mice [J].
Chen, WZ ;
Yan, WY ;
Du, QY ;
Fei, LA ;
Liu, MQ ;
Ni, Z ;
Sheng, ZT ;
Zheng, ZX .
JOURNAL OF VIROLOGY, 2004, 78 (13) :6900-6907
[7]   A solid-phase blocking ELISA for detection of type O foot-and-mouth disease virus antibodies suitable for mass serology [J].
Chénard, G ;
Miedema, K ;
Moonen, P ;
Schrijver, RS ;
Dekker, A .
JOURNAL OF VIROLOGICAL METHODS, 2003, 107 (01) :89-98
[8]  
CURTISS R, 1994, RECOMBINANT SYNTHETI, P340
[9]   Oral somatic transgene vaccination using attenuated S-typhimurium [J].
Darji, A ;
Guzman, CA ;
Gerstel, B ;
Wachholz, P ;
Timmis, KN ;
Wehland, J ;
Chakraborty, T ;
Weiss, S .
CELL, 1997, 91 (06) :765-775
[10]  
Darji A, 2000, FEMS IMMUNOL MED MIC, V27, P341